Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

October 14, 2025

A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13, 2025

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 09, 2025

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 09, 2025

Global Biosimilars Market Sees Gains in Access and Pipeline Expansion

October 07, 2025

Biosimilars Policy Roundup: April 2025

April 30th 2025

By Skylar Jeremias

Article

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar access at Festival of Biologics USA to close out April 2025.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

By Skylar Jeremias

Article

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access

April 28th 2025

By Cameron Santoro

Article

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.

Clinical Evidence Shows No Safety Gaps Between Biosimilar, Reference Adalimumab

April 26th 2025

By Deana Ferreri, PhD

Article

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the originator in a pooled analysis of the VOLTAIRE clinical trials.

The Top 5 Biosimilar Articles for the Week of April 21

April 25th 2025

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of April 21, 2025.

Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market

April 25th 2025

By Cameron Santoro

Article

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

April 24th 2025

By Cameron Santoro

Article

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.

Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain

April 24th 2025

By Cameron Santoro

Article

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.

The Growing Impact of Biosimilars in IBD Care

April 23rd 2025

By Skylar Jeremias

Article

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

By Skylar Jeremias

Article

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.